Received: 7 February 2020
Accepted: 20 July 2020
First Online: 29 July 2020
Ethics approval and consent to participate
: This study was approved by the Ethics Committee of the Tokyo Women’s Medical University (3771). Patients retained the right to opt out.
: Not applicable.
: All authors declare no conflicts of interest related to this study. SK has received speaker’s honoraria from Bayer, Otsuka, Eisai, Chugai and MSD, outside the submitted work. AH reports personal fees from Meiji Seika Pharma, Mochida, Yoshitomiyakuhin, Shinkoh-igaku Publishers and Japan Medical Journal, outside the submitted work. KM has received speaker’s honoraria from Eisai, Meiji Seika Pharma, Mochida, MSD, Otsuka, and Yoshitomiyakuhin, and a research grant from Ministry of Education, Culture, Sports, Science and Technology, outside the submitted work. RA has received personal fees from Cancer Patients Support Organization, Jiho, Ishiyaku Publishers, Igaku-Shoin, Kagakuhyoronsha, Gakken, Seiwa Shoten Publishers, Yoshitomiyakuhin, and Chugai Pharma, outside the submitted work. NK has received speaker’s honoraria from Meiji Seika Pharma, Mochida, Takeda, Yoshitomiyakuhin, Pfizer, Eli Lilly, MSD, Shionogi, Janssen, Eisai, Astellas, Otsuka, Daiichi Sankyo, Nipro, Kissei, Tsumura, Novartis, Mitsubishi Tanabe, and Chugai; he has received research/grant support from Mochida, Takeda, Otsuka, Novartis, Mitsubishi Tanabe, Dainippon Sumitomo, MSD, Eisai, Tsumura, Eli Lilly, GlaxoSmithKline, and Mebix within the past 3 years outside the submitted work.